Premium
Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib
Author(s) -
Zargari Omid,
Azimi Seyyede Zeinab,
Geranmayeh Siamak
Publication year - 2017
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12509
Subject(s) - vismodegib , medicine , basal cell carcinoma , radiation therapy , imiquimod , skin cancer , basal cell , dermatology , adjuvant radiotherapy , hedgehog signaling pathway , surgery , cancer , oncology , signal transduction , biochemistry , chemistry
Basal cell carcinoma (BCC) is the most common skin cancer but usually has a good prognosis. However, there is a subset of BCC cases with a less favorable prognosis. For patients with locally advanced, recurrent or metastatic BCCs who are not suitable for surgery or radiotherapy, small‐molecule drug inhibitors of hedgehog pathway are a new therapeutic opportunity. Here, we present a case of infiltrative BCC with multiple recurrences. Wide excision with reconstructive plastic surgery was performed initially with adjuvant radiotherapy. Due to multiple recurrences afterward, radiotherapy, topical imiquimod and oral itraconazole were used but were not effective. Finally, the patient was treated with vismodegib which led to a complete response. Moreover, the patient's symptoms due to the locally diffused cancer resolved.